L26/P-810 Predictors of follicular response to letrozole in infertile women with polycystic ovary syndrome: a prospective cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1137 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Kamboj und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Which clinical, endocrine, metabolic, and sonographic factors predict follicular response to letrozole in infertile women with polycystic ovary syndrome? Summary answer Elevated Anti Mullerian Hormone, hyperandrogenism, insulin resistance, and higher follicle number per ovary predict poor letrozole response, while extended low-dose regimens improved dominant follicle formation. What is known already Letrozole is the recommended first-line agent for ovulation induction in women with polycystic ovary syndrome (PCOS), offering superior ovulation and live birth rates compared with clomiphene citrate. However, response to letrozole is heterogeneous, and a significant proportion of women require dose escalation or alternative therapies. Previous studies have suggested that endocrine factors such as anti-Müllerian hormone (AMH) and hyperandrogenism may influence response, but most data are retrospective, non-Indian, and lack comprehensive evaluation across PCOS phenotypes and dosing regimens. Study design, size, duration This was a prospective cohort observational study conducted over 23 months (August 2023–June 2025). A total of 200 infertile women with PCOS were recruited and followed for up to three ovulation induction cycles using different letrozole regimens. Participants/materials, setting, methods Infertile women aged 21–38 years with PCOS diagnosed using modified Rotterdam criteria were enrolled at a tertiary care center. Women undergoing ovulation induction with any letrozole-based regimen were included to reflect routine clinical practice and was administered as 2.5 mg for 5 or 10 days, or 5 mg for 5 days. Clinical, endocrine, metabolic, and sonographic parameters were assessed. The primary outcome was dominant follicle development (≥16 mm). Statistical analysis included logistic regression and ANOVA. Main results and the role of chance Overall, 82% of women developed a dominant follicle, and the clinical pregnancy rate was 29.5%. Poor follicular response was significantly associated with higher serum AMH, free androgen index (FAI), body mass index, LH/FSH ratio, insulin resistance (HOMA-IR), and increased follicle number per ovary (FNPO) (p < 0.05). A dose–response relationship was observed across letrozole regimens. The extended 2.5 mg for 10 days regimen demonstrated superior ovulatory response compared with dose escalation to 5 mg, despite similar baseline characteristics. Women requiring 5 mg doses were older and had longer infertility duration. Phenotype-wise analysis showed that phenotype A had the highest representation but the lowest ovulatory and conception rates, while phenotype D demonstrated the most favorable outcomes. Secondary infertility and lower LH/FSH ratio were positively associated with conception. No cases of ovarian hyperstimulation syndrome were observed, and cycle cancellation was uncommon. These findings were statistically robust and consistent across cycles. Limitations, reasons for caution The study was single-center and observational, with smaller numbers in some PCOS phenotypes. Long-term outcomes such as live birth were not evaluated. Wider implications of the findings Identifying predictors of letrozole response enables individualized ovulation induction strategies. Extended low-dose regimens may improve outcomes and reduce unnecessary dose escalation in women with adverse endocrine or metabolic profiles. Trial registration number No
Zitieren
APA
Kamboj, S., Kumari, A., Mahey, R., & Jayaraj, A. (2026). L26/P-810 Predictors of follicular response to letrozole in infertile women with polycystic ovary syndrome: a prospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1137
Vancouver
Kamboj S, Kumari A, Mahey R, Jayaraj A. L26/P-810 Predictors of follicular response to letrozole in infertile women with polycystic ovary syndrome: a prospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1137
BibTeX
@article{Kamboj2026,
author = {Kamboj, S. and Kumari, A. and Mahey, R. and Jayaraj, A.K.},
title = {L26/P-810 Predictors of follicular response to letrozole in infertile women with polycystic ovary syndrome: a prospective cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1137}
}
EUVIMED